Articles

PP40 Anti-Pd1 inhibitor follow by Allo Stem cell transplantation in 3 heavily pretreated lymphoma’s patients: Experience from Institut Jules Bordet

BJH - 2018, issue Abstract Book BHS, february 2018

M. Maerevoet MD, P. Lewalle MD, PhD, N. Meuleman MD, PhD, C. Spilleboudt MD, A. Salaroli MD, S. Wittnebel MD, PhD

Read more

P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation

BJH - 2018, issue Abstract Book BHS, february 2018

M. Vercruyssen MD, N. Cilla , L. Ameye , M. Paesmans , A. De Wind MD, PhD, P. Heimann MD, PhD, N. Meuleman MD, PhD, D. Bron MD, PhD

Read more

Update on therapy of relapsed and refractory multiple myeloma

BJH - volume 8, issue 2, march 2017

M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, PhD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)

SUMMARY

The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.

(BELG J HEMATOL 2017;8(2):53–65)

Read more

P15 Treatment patterns of Waldenström’s macroglobulinemia in Belgium

BJH - volume 8, issue Abstract Book BHS, february 2017

A. Smet , V. Van Hende MD, M. André MD, PhD, C. Bonnet MD, PhD, G. Bries MD, PhD, V. De Wilde MD, PhD, H. Demuynck MD, N. Meuleman MD, PhD, W. Schroyens MD, PhD, A. Van Hoof MD, PhD, M. Giordan , L. de Vos , A. Janssens MD, PhD

Read more

O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, J. Alexis Ruiz , M. Roos , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

PP70 The use of adipose Stromal Vascular Fraction in a Platelet-Rich Fibrin scaffold within Bisphosphonate-Related Osteonecrosis of the Jaw treatment

BJH - volume 8, issue Abstract Book BHS, february 2017

C. Bouland , N. Meuleman MD, PhD, J. Widelec , K. Kambiz , C. Voisin , L. Lagneaux , P. Philippart

Read more

P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life

BJH - volume 8, issue Abstract Book BHS, february 2017

A. Pistone , M. Maerevoet MD, S. Wittnebel MD, PhD, M. Vercruyssen MD, S. Buntinx , C. Spilleboudt MD, D. Bron MD, PhD, N. Meuleman MD, PhD

Read more